The 160-Pound Man Problem: How Drug Dosing Was Built Around a Body That Isn't Yours

A Benchmark Built on Exclusion

In 1977, the U.S. Food and Drug Administration issued guidance that effectively excluded women of childbearing potential from early-phase clinical drug trials. The stated rationale was precautionary — a response, in part, to the thalidomide tragedy of the preceding decade, in which a sedative taken by pregnant women caused severe birth defects. The intention was protective. The consequence, however, was the construction of an entire pharmacological knowledge base derived almost exclusively from male subjects.

That guidance remained in effect until 1993, when the FDA reversed course and required the inclusion of women in clinical trials. By that point, however, the foundational dosing data for hundreds of medications already in widespread use had been established without meaningful representation of female physiology. Many of those dosing standards remain in place today, largely unchanged.

The implications are not abstract. A 2020 analysis published in Biology of Sex Differences found that women experience adverse drug reactions at nearly twice the rate of men. The researchers identified sex-based differences in pharmacokinetics — the way the body absorbs, distributes, metabolizes, and eliminates drugs — as a primary contributing factor. These are not idiosyncratic sensitivities. They are predictable, physiological differences that affect how medications behave in the female body.

The Physiology Behind the Disparity

To understand why the same dose can affect men and women so differently, it helps to consider what actually happens to a drug after it is swallowed.

Women generally have lower body weight and a higher percentage of body fat relative to lean muscle mass than men of comparable age. Because many drugs distribute into fatty tissue, these differences affect how long a medication remains active in the body. Women also tend to have lower kidney filtration rates and different levels of the liver enzymes responsible for metabolizing drugs — particularly the cytochrome P450 enzymes, which process a broad range of common medications including antidepressants, statins, and certain antibiotics.

Hormonal variation adds another layer of complexity. Estrogen and progesterone directly influence drug metabolism, which means a woman's response to a given medication may shift across her menstrual cycle, during pregnancy, or after menopause. Oral contraceptives, which alter hormonal levels substantially, are known to interact with a range of medications — yet this interaction is rarely factored into standard dosing recommendations.

Which Medication Classes Are Most Affected

While sex-based dosing disparities exist across many drug categories, several classes have been particularly well-documented.

Sleep Medications — Zolpidem The clearest and most consequential example of sex-based dosing failure involves zolpidem, the active ingredient in Ambien and several generic sleep aids. For years following its approval, zolpidem was prescribed at the same dose for men and women. In 2013, the FDA took the unusual step of mandating a reduction in the recommended dose for women — cutting the immediate-release dose in half — after data showed that women metabolized the drug significantly more slowly than men. At the original dose, women were waking with measurable amounts of zolpidem still active in their bloodstream, impairing driving ability the following morning. This was not a newly discovered problem; the pharmacokinetic data had been available for years before the FDA acted.

Cardiovascular Medications Aspirin's role in preventing first heart attacks has been studied extensively in men, but evidence for women — particularly younger women — is considerably weaker. More broadly, women have historically been underrepresented in cardiovascular drug trials, contributing to dosing standards that may not reflect female cardiovascular physiology. Women also appear to be more sensitive to certain antiarrhythmic drugs, including some that can paradoxically increase the risk of dangerous heart rhythms at standard doses.

Antidepressants and Psychiatric Medications Women are prescribed antidepressants at significantly higher rates than men and appear to respond differently to several drug classes. Some research suggests women achieve therapeutic plasma concentrations at lower doses of certain selective serotonin reuptake inhibitors, meaning standard doses may represent relative over-medication for some female patients. Antipsychotic medications present a similar pattern, with women generally requiring lower doses to achieve equivalent therapeutic effects — a consideration that is not always reflected in prescribing practice.

Opioid Pain Medications Women report higher pain sensitivity and, in some studies, greater analgesic response to opioids at equivalent doses. Paradoxically, women are also more likely to be undertreated for pain in clinical settings. The interaction between sex-based pharmacokinetics and prescribing bias creates a complex picture that standard dosing guidelines do not adequately address.

Recognizing the Signs of a Dosing Mismatch

For women currently taking prescription medications, certain patterns may suggest a sex-based dosing issue worth discussing with a healthcare provider.

Persistent side effects that began at the initiation of a medication and have not resolved — particularly fatigue, dizziness, cognitive fog, or gastrointestinal disturbance — can sometimes indicate that a standard dose is producing higher-than-intended plasma concentrations. Unusually strong or prolonged responses to medications, such as sedation that extends well beyond the expected window, warrant a conversation about whether the dose is calibrated appropriately.

It is also worth noting that weight-based dosing, which accounts for body composition differences, is used routinely in some clinical contexts — pediatric medicine being the most obvious example — but is applied inconsistently in adult prescribing, where flat-dose standards remain the norm.

Advocating for Individualized Dosing

The growing field of precision medicine offers a framework for moving beyond one-size-fits-all dosing. Pharmacogenomic testing — which analyzes how an individual's genetic profile affects drug metabolism — is increasingly available and covered by some insurance plans. While not universally accessible, it represents a meaningful step toward dosing that accounts for individual variation rather than population averages.

For patients who cannot access pharmacogenomic testing, several practical steps remain available. Requesting a therapeutic drug level test, where applicable, can confirm whether a medication is producing plasma concentrations within the intended therapeutic range. Asking a physician or pharmacist specifically whether sex-based dosing differences have been studied for a newly prescribed medication is a legitimate and reasonable question. And reporting adverse effects promptly — rather than assuming they are inevitable — creates an opportunity to reassess whether the current dose is appropriate.

A Long-Overdue Correction

The exclusion of women from early drug trials was a policy decision made decades ago under circumstances that no longer apply. The pharmacological consequences of that decision, however, continue to shape the dosing standards that govern prescriptions written today. Acknowledging this history is not an indictment of modern medicine — it is a necessary starting point for improving it.

Women who experience unexpected or persistent adverse effects from medications are not being oversensitive. In many cases, they are experiencing a predictable physiological response to a dose that was never designed with their bodies in mind. Understanding that distinction is the first step toward a more informed, and more productive, conversation with your healthcare provider.